A Study to Evaluate the Bioequivalence of Orfadin Capsules 20 mg Compared to Orfadin Capsules 10 mg. An Open-label, Randomized, Cross-over, Single-dose Study in Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 02 Dec 2014
At a glance
- Drugs Nitisinone (Primary)
- Indications Parkinson's disease; Tyrosinaemia type I
- Focus Pharmacokinetics
- Sponsors Swedish Orphan Biovitrum
- 01 Jun 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 27 May 2013 New trial record